Imaging targeted at tumor with 188Re-labeled VEGF189 exon 6-encoded peptide and effects of the transfecting truncated KDR gene in tumor-bearing nude mice

Nuclear Medicine and Biology

Volumn 36, Issue 5, 2009, Pages 535-543

  Qin, Zhe xue ^a   Li, Qian wei ^a   Liu, Guang yuan ^a   Luo, Chao xue ^a   Xie, Gan feng ^a   Zheng, Lei ^a   Huang, Ding de ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

188Re; Peptides; Radiolabeled proteins; Radionuclide therapy; Receptor imaging; Tumor imaging

Indexed keywords

ADENOVIRUS VECTOR; RHENIUM 188; UNCLASSIFIED DRUG; VASCULOTROPIN 189 RE 188; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG ELIMINATION; HALF LIFE TIME; HUMAN; HUMAN CELL; INTESTINE; KIDNEY; LIVER; MOUSE; NONHUMAN; RABBIT; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EXONS; GENE DELETION; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGOPEPTIDES; RABBITS; RADIOISOTOPES; RHENIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 67349200945     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.02.001     Document Type: Article

References (28)

1. Neufeld G., Cohen T., Gengrinovitch S., et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 (1999) 9-22
2. Claffey K.P., Brown L.F., del Aguila L.F., Tognazzi K., Yeo K.T., Manseau E.J., et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56 (1996) 172-181
3. Zhang H.T., Craft P., Scott P.A., Ziche M., Weich H.A., Harris A.L., et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87 (1995) 213-219
4. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
5. 189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. Int J Oncol 26 (2005) 1517-1524
6. Jia H., Jezequel S., Lohr M., Shaikh S., Davis D., Soker S., et al. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. Biochem Biophys Res Commun 283 (2001) 164-173
7. Bainbridge J.W., Jia H., Bagherzadeh A., Selwood D., Ali R.R., and Zachary I. A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo. Biochem Biophys Res Commun 302 (2003) 793-799
8. Otrock Z.K., Makarem J.A., and Shamseddine A.I. Vascular endothelial growth factor family of ligands and receptors: Review. Blood Cell Mol Dis 38 (2007) 258-268
9. Peters K.G., De Vries C., and Williams L.T. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci U.S.A. 90 (1993) 8915-8919
10. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Dvorak H.F., et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143 (1993) 1255-1262
11. Yoshiji H., Gomez D.E., Shibuya M., and Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56 (1996) 2013-2016
12. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187 (1992) 1579-1586
13. Sepp-Lorenzino L., Rands E., Mao X., Connolly B., Shipman J., Antanavage J., et al. A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo. Cancer Res 64 (2004) 751-756
14. Kozin S.V., Boucher Y., Hicklin D.J., Bohlen P., Jain R.K., and Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61 (2001) 39-44
15. Drevs J., Hofmann I., Hugenschmidt H., Wittig C., Madjar H., Muller M., et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60 (2000) 4819-4824
16. Meyer R.D., Singh A.J., and Rahimi N. The carboxyl terminus controls ligand-dependent activation of VEGFR-2 and its signaling. J Biol Chem 279 (2004) 735-742
17. 3 for technetium-99m labeling of DNA. Nucl Med Bio1 24 (1997) 425-432
18. 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting. Appl Radiat Isot 64 (2006) 971-978
19. Kiselyov A., Balakin K.V., and Tkachenko S.E. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 16 (2007) 83-107
20. Blankenberg F.G., Mandl S., Cao Y.A., O'Connell-Rodwell C., Contag C., Mari C., et al. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med 45 (2004) 1373-1380
21. Blankenberg F.G., Backer M.V., Levashova Z., Patel V., and Backer J.M. In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging 33 (2006) 841-848
22. Hsu A.R., Cai W., Veeravagu A., Mohamedali K.A., Chen K., Kim S., et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 48 (2007) 445-454
23. Jayson G.C., Zweit J., Jackson A., Mulatero C., Julyan P., Ranson M., et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94 (2002) 1484-1493
24. Li S., Peck-Radosavljevic M., Koller E., Koller F., Kaserer K., Kreil A., et al. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer 91 (2001) 789-796
25. 123I-VEGF165 as a potential tumor marker. Nucl Med Biol 32 (2005) 431-436
26. 3: a comparison of radiochemical behavior and biological efficacy with other labelling methods. Nucl Med Biol 25 (1998) 395-403
27. Rusckowski M., Qu T., Gupta S., Ley A., and Hnatowich D.J. A comparison in monkeys of (99m)Tc labeled to a peptide by 4 methods. J Nucl Med 42 (2001) 1870-1877
28. 99mTc-neutrophil elastase inhibitor in monkeys. J Nucl Med 41 (2000) 363-374